Parkinson S Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for parkinson s disease. 189 active patents protecting 5 drugs from 5+ originators. First major cliff: 2029. Daily refresh.

5
Approved drugs
189
Active US patents
58/100
Avg vulnerability
—
Annual revenue covered

Originators in Parkinson S Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Aton 151 patents UCB 24 patents Merz 6 patents AbbVie GK 4 patents Kyowa Kirin 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating parkinson s disease. Each bar = one year. Y-axis scaled to peak year (64 patents).

8
27
34
28
1
29
12
30
10
32
1
33
64
34
3
35
3
39
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sinemet Cr
CARBIDOPA
 Aton 151 53 — 2028-12-26
Neupro
ROTIGOTINE
 UCB 24 56 — 2027-09-01
Inbrija
LEVODOPA
 Merz 6 53 — 2029-02-03
FOSCARBIDOPA AbbVie GK 4 61 — 2035-10-21
Nourianz
ISTRADEFYLLINE
 Kyowa Kirin 4 65 — 2027-09-05

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
7727993 Nourianz method of use 75 2028-01-28
7727993 Nourianz method of use 75 2028-01-28
RE43711 Inbrija method of use 75 2029-02-03
12458615 Inbrija method of use 75 2033-10-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10730895 FOSCARBIDOPA composition of matter 17 2035-10-21
12303605 Sinemet Cr formulation 38 2034-10-07
12064521 Sinemet Cr formulation 38 2034-10-07
11357733 Sinemet Cr formulation 38 2034-10-07
11622941 Sinemet Cr formulation 38 2034-10-07
11622941 Sinemet Cr formulation 38 2034-10-07
12178918 Sinemet Cr formulation 38 2034-10-07
12064521 Sinemet Cr formulation 38 2034-10-07
12064521 Sinemet Cr formulation 38 2034-10-07
11622941 Sinemet Cr formulation 38 2034-10-07

Related